Serpex Medical appears in FDA premarket records as the applicant for cryosurgical biopsy instruments carrying the Maverix name. The supplied collection holds one linked 510(k) record, K262420, decided September 2, 2026 with decision code SESE, meaning substantially equivalent. The same collection's record sample contains that single entry, so the sample decision count of one SESE matches the full collection count of one SESE. These figures describe the supplied filings as of the snapshot date and are not measures of sales, total portfolio or safety performance. [1][2][3]

The K262420 clearance and its scope

K262420 covers the Maverix Cryo Biopsy Pro (MCB Pro) (MCBP-1000) and the Maverix Cryo Cartridge (CC-1000). The FDA record lists Serpex Medical at 3350 Scott Blvd., Suite 37b, Santa Clara, California 95054, with the application received July 16, 2026 and a decision date of September 2, 2026. The clearance type is Traditional, the third-party flag is N, and the review advisory committee is General, Plastic Surgery. The decision description reads Substantially Equivalent, and the record indicates a Summary rather than a statement. [1]

The FDA clearance letter for K262420 repeats the trade names and identifies the regulation as 21 CFR 878.4350, Cryosurgical unit and accessories, Class II, product code GEH. The letter is addressed to Krystal Santiago in Regulatory Affairs at the same Santa Clara address and carries a document date of July 15, 2026 with receipt in July. The correspondence address in a filing is not evidence of a corporate headquarters. [3]

Device characteristics described in the filings

The K262420 review document describes two tip configurations: a blunt tip exposed during placement through an endoscope at 1.1 or 2.4 mm outer diameter, and a pointed tip that is sheathed during placement and exposed at the target tissue location, with minimum outer diameter 0.8 mm and maximum 1.2 mm. Activation is listed as either a footswitch connected to a console or an inline handle on the probe assembly. The document also mentions a stop on the inline handle and an adjustable outer sheath with a locking function. [3]

A substantial-equivalence comparison in the K261068 review document sets the Maverix Cryo Biopsy Probe and Accessories against K190651 ERBECRYO 2 Cryosurgical Unit and Accessories. For flexible cryoprobes, patient contact materials are listed as stainless steel, silicone and plastics for the predicate and stainless steel and plastics for the Maverix device, with contact duration limited to under 24 hours for both. The same table repeats the blunt and pointed tip descriptions and the footswitch or inline handle activation options. [5]

Related filings and published product material

An earlier Serpex Medical submission, K261068, names the Maverix Cryo Biopsy Probe (MCB1000) and Maverix Cryo Cartridge (CC1000) under the same regulation, class and product code, dated March 31, 2026 and received April 1, 2026. That record is not part of the supplied collection counts; it is referenced here only as a separate filing document. [5]

A Maverix CryoBiopsy Probe instructions-for-use document, identified as LB006 revision C, states that the probe may only be used by a qualified medical professional trained in its use. Its symbol glossary references ISO 15223-1 entries and prescription-only labeling under 21 CFR 801.109, and its further-information section directs inquiries to a Serpex Medical representative at Serpex Medical Inc., 3350 Scott Blvd, Suite 37B, Santa Clara. [4]

Maverix Medical's own website describes endobronchial tissue-sampling instruments intended to help physicians obtain tissue for diagnosis, alongside risk-assessment and intervention portfolios. That description is the publisher's characterization of the Maverix brand and is not attributed to Serpex Medical in the public documents. [8]

What the record does and does not establish

The public information documents a single Serpex Medical 510(k) entry, K262420, with a substantially equivalent decision, and does not establish commercial availability, customers, clinical performance or certifications. The relationship between Serpex Medical as legal applicant and Maverix Medical as a brand publisher is not stated in the public documents, so any parent, ownership or corporate structure remains unknown. [1][8]